Century Therapeutics, Inc. (IPSC)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | - | 109,164 | 791 | 771 |
| Research and development | 26,859 | 26,580 | 27,228 | 27,220 |
| General and administrative | 7,805 | 8,408 | 8,352 | 8,306 |
| Total operating expenses | 34,664 | 34,988 | 35,580 | 35,526 |
| Income (loss) from operations | -34,664 | 74,176 | -34,789 | -34,755 |
| Other income (expense) | 113 | -38 | 250 | -12 |
| Interest income | 2,010 | 2,422 | 3,305 | 3,582 |
| Total other income | 2,123 | 2,384 | 3,555 | 3,570 |
| Income (loss) before provision for income taxes | -32,541 | 76,560 | -31,234 | -31,185 |
| Income tax expense (benefit) | - | - | -8 | 22 |
| Net income (loss) | -32,541 | 76,560 | -31,226 | -31,207 |
| Unrealized loss on investments | -222 | -19 | 1,075 | -102 |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent | - | - | -8 | 34 |
| Comprehensive income (loss) | -32,763 | 76,541 | -30,159 | -31,275 |
| Earnings per share, basic | -0.38 | 0.89 | -0.37 | -0.38 |
| Earnings per share, diluted | -0.38 | 0.89 | -0.37 | -0.38 |
| Weighted average number of shares outstanding, basic | 86,238,084 | 86,021,188 | 84,704,352 | 82,092,167 |
| Weighted average number of shares outstanding, diluted | 86,238,084 | 86,098,619 | 84,704,352 | 82,092,167 |